Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 18/20 | 0.68 |
| ▸ | ICAM1 | P05362 | 18/20 | 0.68 |
| ▸ | ITGAL | P20701 | 18/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453167 | 1.00 | ITGB2 (0.68) | ITGB2ICAM1ITGALKDM4EMAPT | |
| SCHEMBL5447059 | 0.93 | ITGB2 (0.66) | ITGB2ICAM1ITGALKDM4EMAPT | |
| SCHEMBL5220946 | 0.92 | ITGB2 (0.67) | ITGB2ICAM1ITGALKDM4EMAPT | |
| SCHEMBL5447064 | 0.90 | ITGB2 (0.68) | ITGB2ICAM1ITGALKDM4EMAPT | |
| SCHEMBL5451106 | 0.90 | ITGB2 (0.68) | ITGB2ICAM1ITGALKDM4EMAPT | |
| SCHEMBL5451663 | 0.85 | ITGB2 (0.68) | ITGB2ICAM1ITGAL | |
| SCHEMBL5453520 | 0.85 | ITGB2 (0.68) | ITGB2ICAM1ITGAL | |
| SCHEMBL14362409 | 0.81 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL5445559 | 0.81 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL14362562 | 0.81 | ITGB2 (1.00) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259863-A1 | Arylphenylamino-,Arylphenylamide-, and Arylphenylether-Sulfide Derivatives | ICOS CORPORATION (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259863-A1 | Arylphenylamino-,Arylphenylamide-, and Arylphenylether-Sulfide Derivatives | AHR, ARSA, TST | ITGB2 3194/4885ICAM1 1146/4885ITGAL 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.